ARCT

Arcturus Therapeutics

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$307M

Burn Rate (Qtr)

$10.3M

Company Profile

Arcturus Therapeutics is developing a portfolio of mRNA therapeutics for treatment of diseases with unmet medical needs. Our hope and vision are to build transformative, life-changing medicines for patients and their families.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

COVID-19 Vaccine (ARCT-021)

COVID-19

Phase 1/2 Data

Q4 2020

ARCT-810

OTC (Ornithine Transcarbamylase) Deficiency

Phase 1 Data Readout

Q4 2020

Recent Posts

See what the community is saying - click to see full post

Small Cap COVID-19 Vaccine Players

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon